基于脂质代谢与体重的IgA肾病预后评估：TCBI的潜在价值

Prognostic Value of TCBI for IgA Nephropathy Patients Based on Lipid Metabolism and Body Weight

摘要: IgA肾病(IgAN)是全球最常见的原发性肾小球疾病。现有研究表明，血脂异常和肥胖可通过加速系膜细胞增生、足细胞损伤及肾间质纤维化等机制驱动疾病进展。日本学者Doi等近年首次提出的新型营养指数TCBI (甘油三酯 × 总胆固醇 × 体重指数/1000)已在心血管疾病领域显示出良好的预后预测价值，但其在IgAN中的应用尚未见报道。本文系统阐述了IgAN的免疫–补体–足细胞发病机制，梳理了脂代谢紊乱与肾脏组织学损伤的相互作用关系，并总结TCBI的理论基础、计算方法及心血管领域的实证研究。基于现有证据，本文提出：TCBI通过整合全身代谢应激为单一指标，有望成为评估IgAN疾病活动度及预测远期肾脏结局的代谢窗口指标。未来需开展大规模、多中心、前瞻性研究以明确TCBI与组织学病变、蛋白尿动态变化及硬终点事件的量化关系，并探索基于TCBI的精准干预策略。

Abstract: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Accumulating evidence indicates that dyslipidemia and obesity accelerate mesangial proliferation, podocyte injury, and renal interstitial fibrosis, thereby driving disease progression. The novel nutritional index TCBI (triglyceride × total cholesterol × body weight/1000), first proposed by Doi et al. in 2018, has demonstrated robust prognostic value in cardiovascular disorders; however, its application in IgAN remains unexplored. This review systematically delineates the immune-complement-podocyte pathogenesis of IgAN, elucidates the interplay between lipid dysregulation and renal histological damage, and summarizes the theoretical basis, calculation method, and cardiovascular validation of TCBI. Based on current evidence, we propose that TCBI, by integrating systemic metabolic stress into a single metric, holds promise as a metabolic window for assessing disease activity and predicting long-term renal outcomes in IgAN. Large-scale, multicenter, prospective studies are warranted to quantify its associations with histological lesions, proteinuria dynamics, and hard renal endpoints, and to explore TCBI-targeted interventions for precision nephrology.